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a  b  s  t  r  a  c  t
Skin  has  gained  substantial  attention  as  a  vaccine  target  organ  due  to  its immunological  properties,  which
include  a high  density  of professional  antigen  presenting  cells  (APCs).  Previous  studies  have  demonstrated
the effectiveness  of  this  vaccination  route  not  only  in  animal  models  but also  in  adults.  Young  children
represent  a  population  group  that  is  at high  risk  from  inﬂuenza  infection.  As a result,  this group  could  ben-
eﬁt signiﬁcantly  from  inﬂuenza  vaccine  delivery  approaches  through  the  skin  and  the  improved  immune
response  it  can  induce.  In this  study,  we compared  the  immune  responses  in young  BALB/c  mice  upon
skin delivery  of  inﬂuenza  vaccine  with  vaccination  by  the  conventional  intramuscular  route.  Young  mice
that  received  5 g of H1N1  A/Ca/07/09  inﬂuenza  subunit  vaccine  using  MN  demonstrated  an  improved
serum  antibody  response  (IgG1  and  IgG2a)  when  compared  to the  young  IM  group,  accompanied  by
higher  numbers  of inﬂuenza-speciﬁc  antibody  secreting  cells  (ASCs)  in  the  bone  marrow.  In addition,
we  observed  increased  activation  of follicular  helper  T  cells  and  formation  of germinal  centers  in the
regional  lymph  nodes  in  the MN immunized  group,  rapid  clearance  of  the  virus  from  their  lungs  as  well
as  complete  survival,  compared  with  partial  protection  observed  in  the  IM-vaccinated  group.  Our  results
support  the hypothesis  that  inﬂuenza  vaccine  delivery  through  the  skin  would  be beneﬁcial  for  protecting
the  high-risk  young  population  from  inﬂuenza  infection.
©  2015  Published  by Elsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Inﬂuenza virus is one of the most common respiratory
pathogens and one of the most frequent causes of upper respiratory
tract infection [1]. When infection occurs in adults, the course of the
illness is often mild and self-limited, without the need for medical
care or antiviral drugs in most cases, and the expected recovery
time is less than two weeks [2,3]. There are however groups at high
risk from inﬂuenza infection, in which the disease severity is much
greater than that observed in adults. These include the elderly over
∗ Corresponding author at: Department of Microbiology & Immunology, Emory
University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, United States.
Tel.: +1 404 727 2015; fax: +1 404 727 3295.
E-mail address: rcompan@emory.edu (R.W. Compans).
65 [4,5], persons with underlying chronic diseases [6,7], infants and
children 5 years of age and younger who have not been previously
exposed to the virus [8,9], and pregnant women [10,11]. Inﬂuenza
infection among these groups is often followed by secondary com-
plications such as sinus infection, bronchitis, pneumonia as well as
failure of other organs such as the heart and the kidneys, occasion-
ally resulting in death [12,13]. Infants and children 5 years of age
and younger represent one of the most susceptible groups and have
increased mortality rates [2,14].
Annual vaccination is the most effective method of protection
against inﬂuenza infection [15]. Despite recommendations for vac-
cination targeted to high-risk groups and their contacts, the CDC
estimates that 36,000 deaths and 1.7 million hospitalizations can
be attributed to seasonal inﬂuenza infection annually in the U.S.
[16,17], with highest disease severity and mortality among high-
risk groups [18,19]. While inﬂuenza vaccines can be highly effective
http://dx.doi.org/10.1016/j.vaccine.2015.01.086
0264-410X/© 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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in adults, there are reduced beneﬁts in young children leaving them
vulnerable to infection [20,21]. Live attenuated inﬂuenza vaccine
(LAIV) is not approved for children under 2 due to safety concerns
[22,23]. Several studies have demonstrated the limited ability of
inactivated inﬂuenza vaccine to induce strong humoral and cellu-
lar immune responses in young children, potentially because of the
immaturity of their immune system as well as lack of prior exposure
to inﬂuenza viral antigens [24–26]. As a result of reduced protec-
tion, the CDC issued new guidelines recommending 2 or more doses
of seasonal inﬂuenza vaccine for this age group. This approach,
however, can be associated with compliance and timeline issues
which limit the desired results. These factors support the need for
new vaccine formulations and alternative vaccination routes that
will increase compliance, and improve protective immunity, in this
high-risk population [27,28].
Several studies have demonstrated that delivery of inﬂuenza
vaccine through the skin of adult mice, using different types of
microneedle patches (MN), leads to enhanced immune responses
and improved duration of protective immunity when compared to
conventional intramuscular delivery (IM) [29–31]. Because of these
promising results, and other studies [32,33] that demonstrated
improved immune responses in humans after intradermal deliv-
ery of inﬂuenza antigen using reduced doses, the skin has gained
attention as an attractive target for vaccine delivery.
Here we investigate delivery of a single dose of subunit inﬂuenza
vaccine through the skin with microneedle patches in 2 week old
mice and compare the results to those observed in young mice
immunized through the conventional intramuscular route. The
results support the advantages of skin vaccination using inﬂuenza
vaccines not only for adults but also for infants and young children,
highlighting new vaccination strategies that will improve protec-
tive immunity.
2. Materials and methods
2.1. Microneedle fabrication and coating
As previously described [29] metal microneedles were fab-
ricated by laser etching stainless steel sheets (McMaster-Carr,
Atlanta, GA). Each microneedle measured 700 m tall, with a cross
sectional area of 170 m by 55 m at the base and tapering to a
sharp tip, with ﬁve microneedles per row. The size of microneed-
les was selected based on the depth of skin antigen presenting
cell populations that are targeted for vaccine delivery and optimal
immune response [34]. Microneedles were dip-coated as described
[31].
2.2. Cells and viruses
MDCK cells were maintained in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) (Mediatech, Herndon, VA) containing 10% fetal
bovine serum (Hyclone, Rockford, IL). Inﬂuenza virus stocks
(A/California/07/2009) were prepared, puriﬁed and inactivated as
previously described [30]. Hemagglutination (HA) activity was
determined using turkey red blood cells (LAMPIRE, Pipersville, PA).
Mouse-adapted virus was prepared by serial passage 8 times in
lungs of BALB/c mice. The LD50 was calculated by the method of
Reed&Muench, and viral titer was determined by plaque assay
[29,30].
2.3. Immunizations and characterization of immune responses
Female BALB/c mice (Charles River, Wilmington, MA)  (20 mice
per group, 2 weeks old) received one dose (5 g) of a licensed
subunit A/California/07/2009 vaccine (obtained from Novartis
Pharmaceuticals) through the skin using antigen-coated MN arrays
or IM injection as described [31]. The sites of immunization for
both MN and IM delivery were the upper gluteal quadrants of both
legs and near the dorsal side. Animals were bled retro-orbitally
2 and 4 weeks post-immunization under systemic anesthe-
sia. Anti-Ca/07/09 speciﬁc IgG, IgG1, and IgG2a antibody levels
were determined quantitatively by enzyme-linked immunosor-
bent assay (ELISA) as described [35]. The 96-well plates were coated
with 2 g of subunit A/Ca/07/09 vaccine. Puriﬁed mouse IgG, IgG1,
and IgG2a and goat anti-mouse-HRP for ELISA were purchased from
Southern Biotechnology Associates (Birmingham, AL). Optical den-
sity was  read at 490 nm.  We  determined the hemagglutination
inhibition (HAI) titers based on the WHO  protocol as described
previously [35]. Heat-inactivated sera were treated with receptor-
destroying neuraminidase (RDE) (Roche Diagnostics, Indianapolis,
IN) overnight at 37 ◦C, heat inactivated for 30 min  at 56 ◦C and
incubated with packed turkey RBC for 1 h at 4 ◦C to remove any
cryoglobulins interfering with the agglutination reaction. They
were serially diluted and pre-incubated at room temperature with
4 HA Units/50 l of A/Ca/07/09 virus for 30 min. An equal volume
of 0.5% turkey red blood cells was  then added to each well for
30 min  incubation at room temperature. The HAI titer was  read
as the reciprocal of the highest dilution of serum that conferred
inhibition of hemagglutination. The values were expressed as the
geometric mean ± standard deviation.
Virus microneutralization assay was performed as described
previously [CDC Inﬂuenza manual Rev 06FEB98] with modiﬁca-
tions [31]. Brieﬂy, 50 ml  of virus diluent containing 100 xTCID50
of each virus was incubated with 50 ml  of serially diluted heat-
inactivated sera at 37 ◦C for 1 h, and then mixed with 100 ml  of
freshly trypsinized low-passage MDCK cell suspension (ATCC #
CRL-2936) containing 50,000 cells per well in 96-well tissue plates.
The controls wells contained cells alone (negative control) and cells
infected with virus (positive control). Following an 18–22 h incu-
bation period the cells were ﬁxed with acetone and the infected
wells were detected by ELISA. Mouse monoclonal biotinylated
anti-NP antibody MAB8257B (Millipore, Temecula, CA), and HRP-
streptavidin conjugate (BD # 51-9000209, BD Biosciences, San Jose,
CA), were used in the ELISA. Color was  developed using OPD sub-
strate (#002003 Invitrogen, Frederick, MD)  and optical density was
measured at 490 nm in plate reader (model 680 BioRad, Hercules,
CA). The highest serum dilution that generated 50% speciﬁc signal
was considered to be the neutralization titer; 50% speciﬁc signal =
(OD490 virus control - OD490 cell control)/2 + OD490 cell control.
One month post-immunization, mice (n = 5) were challenged
with 5xLD50 of mouse-adapted H1N1 A/California/07/2009 virus
and were monitored for 14 days for signs of morbidity (body weight
changes, fever and hunched posture) and mortality. Weight loss
exceeding 25% was used as the experimental end point, at which
mice were euthanized according to IACUC guidelines. The mouse-
adapted virus was produced by 8 serial passages in mouse lungs.
One month post immunization and four days post-challenge of
an independent cohort, lungs were collected to determine levels
of viral replication, and bone marrow was collected to determine
inﬂuenza-speciﬁc IgG, IgG1 and IgG2a antibody-secreting cells
(ASC) by ELISPOT [29]. Lung viral titers were measured per gram
of tissue from lunch homogenates prepared in DMEM serum-free
medium as previously described [35]. For ELISPOT assay, 96-well
plates were coated overnight at 4 ◦C with subunit A/Ca/07/09 vac-
cine at a ﬁnal concentration of 2 g/ml. The plates were washed
three times with RPMI medium and blocked for 2 h with 10% fetal
calf serum prior to sample addition. Single cell suspensions from
bone marrow collected at 4 days after challenge (0.5–1 × 106/well)
in cRPMI medium were plated directly on coated blocked plates and
were incubated at 37 ◦C for 16 h. Virus-speciﬁc ASC were detected
as spots after incubation with goat anti-mouse IgG horseradish
peroxidase (Southern Biotechnology) and developed with stable
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Fig. 1. Comparison of humoral immune responses induced by skin vs. intramuscular immunization. Serum samples from 2 week old mice were collected at 2 and 4
weeks  post immunization and analyzed for the levels of functional antibody titers against A/California/07/09 by HAI (A), total serum IgG titers (B), and the IgG isotypes, IgG1
(C)  and IgG2a (D) by quantitative ELISA. MN adult: adult microneedle immunized group, IM adult: adult intramuscularly immunized group MN  young: young microneedle
immunized group, IM young: young intramuscularly immunized group. ELISA antibody results represent the mean ± SD. The HAI titers were read as the reciprocal of the
highest  dilution of serum that conferred inhibition of hemagglutination. *p < 0.05, **p < 0.005, ***p < 0.0001.
diaminobenzidine (Research Genetics). Samples were enumerated
in an ELISPOT reader (Cellular Technology, Shaker Heights, OH) and
the results shown as the number of ASC per 106 cells [35].
Regional (inguinal) lymph nodes and spleens were collected 7
days and 14 days post-vaccination for the evaluation of activated
follicular T helper cells and germinal center formation by FACS. Sin-
gle cell suspensions were incubated with Fc-block (2.4G2) on ice
for 15 min  before staining with PNA-FITC, Fas-PE, PD-1-PE-Texas
Red, CXCR5-APC, CD44-APC-e780, CD19-e450, CD4-BV510, CD3-
BV650, and CD8-BV785 antibodies for 30 min  on ice. Antibodies
were purchased from BD Biosciences, eBiosciences, and BioLegend.
Cells were washed and ﬁxed in 1% paraformaldehyde for 30 min
at room temperature prior to analysis. Samples were acquired
on a LSR II ﬂow cytometer (BD Biosciences) and data were ana-
lyzed with FlowJo software (Tree Star). Serum samples and lung
homogenates were individually processed to determine humoral
immune responses and neutralization titers respectively. All ani-
mal  studies had approval of Emory’s Institutional Animal Care and
Use Committee.
2.4. Statistics
The statistical signiﬁcance of differences was calculated by two-
tailed unpaired Student’s t-test and one-way ANOVA (one-way
analysis of variance including Bonferroni’s multiple comparison
test) or two-way ANOVA. Values of p ≤ 0.05 were considered sig-
niﬁcant. Unless otherwise stated, independent experiments were
run at least in triplicate.
3. Results
3.1. Humoral immune responses after MN or IM delivery of
inﬂuenza subunit vaccine
In order to assess the effectiveness of inﬂuenza vaccination in
young populations, we  ﬁrst measured the levels of functional anti-
body titers against the hemagglutinin antigen (HA) of inﬂuenza
virus induced after the skin delivery with MNs  or intramuscularly
immunization. Although no signiﬁcant responses were measured
as soon as day 14, young mice that received inﬂuenza subunit
vaccine through the skin using MN  patches demonstrated signiﬁ-
cantly higher HAI titers at day 28 post vaccination when compared
to IM-immunized young mice (Fig. 1A). The HAI  titers in young
mice that were immunized through the skin were similar to the
HAI titers measured in control immunized adult mice vaccinated
with either IM or MN routes. In addition, these results were fur-
ther supported by signiﬁcantly higher microneutralization titers
measured in serum samples from MN immunized young mice 28
days post-vaccination (supplementary Fig. 1). These results indi-
cate that delivery of subunit inﬂuenza vaccine through the skin
using MN patches in young mice induces higher levels of functional
antibodies when compared to IM immunization.
We furthermore determined the levels of inﬂuenza-speciﬁc cir-
culating IgG antibodies in sera of young mice vaccinated by either
MN or IM routes. At two and four weeks post-vaccination, young
mice that were immunized via the skin exhibited signiﬁcantly
higher total anti-inﬂuenza speciﬁc antibody titers when compared
to mice immunized IM (Fig. 1B). We  also measured signiﬁcantly
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Fig. 2. Protective efﬁcacy of immunization against H1N1 A/California/07/2009 lethal infection and analysis of lung viral titers. Body weight changes (A) and survival
rates  (B) were recorded after lethal challenge with 5xLD50 of A/California/07/2009 virus in young MN and IM immunized mice 2 weeks post immunization and naïve mice.
Lung  viral titers (C) were determined by plaque assay. INF: infected mice. Data represent the mean ± SD, *p < 0.05, **p < 0.005, ***p < 0.0001.
higher levels of both IgG1 and IgG2a isotypes in young mice vac-
cinated by MN which were 2 or 3-fold higher respectively when
compared to young mice that were immunized via the IM route
(Fig. 1C and D). A signiﬁcant ﬁnding is the low levels of IgG2a anti-
bodies measured in IM vaccinated mice, which could indicate the
lack of development of this arm of the immune system in young
mice after IM immunization. Several studies have demonstrated the
distinct contribution and important roles these isotypes play dur-
ing protection. We  have previously demonstrated that the proﬁle
of the immune responses is affected by the route of immunization
[29,30]. In this study, young mice that received the subunit vaccine
through the MN  route exhibited similar levels of IgG2a antibodies
as found in adult mice immunized by MN.  Although no signiﬁcant
difference in immune response was observed in IM vs. MN vac-
cinated adult mice 28 days post-vaccination, we have previously
demonstrated the effectiveness of MN  delivery of inﬂuenza vac-
cine to induce improve immune responses that are long lasting
[29]. Overall, the immune response in young mice after MN  delivery
was similar to that seen in adults after IM or MN  vaccination. These
results indicate that MN  delivery of inﬂuenza subunit vaccine in
young mice induces higher anti-inﬂuenza speciﬁc antibodies when
compared to the titers observed in young mice immunized by the
IM route, and a more closely balanced isotype antibody response.
3.2. Protection against lethal inﬂuenza infection
In order to compare the protective capacity of the immune
response induced in young mice after delivery of inﬂuenza sub-
unit vaccine by MN  or IM delivery, we challenged mice from
both groups with 5xLD50 of mouse adapted H1N1 A/Ca/07/09
virus by intranasal inoculation with 50 l of the virus. After chal-
lenge, all mice were followed for 14 days for signs of morbidity
(body weight changes, fever and hunched posture) and mortal-
ity. As seen in Fig. 2A, young mice immunized by the IM route
exhibited a higher body weight loss when compared to the body
weight changes in young mice immunized via the skin. Addi-
tionally, young mice immunized IM were only partially protected
after lethal challenge, with a mortality rate of 40%. In contrast,
young mice that were immunized via the skin with MN patches
demonstrated 100% survival (Fig. 2B). The improved protection
observed in the young MN immunized mice is reﬂected by reduced
virus titers measured in the lungs of these mice one month post
vaccination and 4 days post challenge. In young mice that were
immunized by the IM route, we observed high virus titers with
a 1 log decrease when compared to unimmunized infected ani-
mals (Fig. 2C). In contrast, young MN-immunized mice exhibited
a 4 log decrease in lung virus titers when compared to the unim-
munized group. Although delivery of inﬂuenza vaccine using MN
patches conferred completed survival, mice from both MN and IM
immunized groups exhibited signs of disease with more intense
symptoms in the IM group. This is not surprising since both MN
and IM immunization represent systemic routes of vaccine deliv-
ery not capable of inducing sterilizing immunity, which can be
induced by intranasal vaccination [36]. These results demonstrate
the induction of more effective protective immune responses after
MN delivery of subunit inﬂuenza vaccine in young mice, and a
rapid clearance of the virus from their lungs, leading to complete
survival.
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Fig. 3. Comparison of bone marrow plasma cell levels after IM or MN immunization. The numbers of inﬂuenza-speciﬁc IgG (A) and IgG1 (B) and IgG2a (C) plasma cells in
the  bone marrow were determined by ELISPOT 4 weeks after a single immunization. The cells were cultured in the presence of 4 g/ml subunit A/California/07/2009 vaccine
and  16 h later the numbers of plasma cells in the bone marrow from young MN and IM vaccinated mice, adult MN and IM vaccinated mice and unvaccinated mice were
determined. Plasma cell numbers of vaccinated mice were considered positive if the numbers of spots were higher than the sum of naïve infected group spots + 3xSDev. N:
naïve  mice. Data represent the mean ± SD, *p < 0.05, **p < 0.005, ***p < 0.0001.
3.3. Evaluation of long-lived bone marrow plasma cells
To further investigate the improved immune responses when
compared to IM immunization, we measured the levels of long-
lived inﬂuenza virus-speciﬁc IgG plasma cells in the bone marrow
and IgG1 and IgG2a isotypes at 4 weeks after a single vaccination.
Young mice that received the vaccine through the skin via MNs
exhibited a two-fold higher number of IgG ASCs in the bone marrow
when compared to the numbers measured in the IM group (Fig. 3A).
Furthermore, we observed signiﬁcantly higher numbers of IgG1
(p < 0.005) ASCs in the MN  group when compared to IM,  and three-
fold higher levels of IgG2a ASCs in the young mice immunized via
MN in comparison to IM immunized mice (Fig. 3B and C). The levels
of ASCs in the young mice immunized with MN  patches were sim-
ilar to levels measured in MN  vaccinated adult mice controls. The
increased numbers of inﬂuenza virus-speciﬁc long-lived plasma
cells in the bone marrows of young mice vaccinated by MNs  corre-
late with the higher serum antibody levels observed in these mice,
and also correspond with the isotype difference observed between
MN and IM vaccinated young mice. These differences reﬂect the
improved humoral immune responses in young MN  mice and the
differences in protection observed among these groups after lethal
inﬂuenza challenge.
3.4. Cellular immune responses in the lungs and spleens of
vaccinated young mice
The levels of CD4+ and CD8+ IFN- T-cells in the lungs and
spleens of young mice vaccinated by MN  or IM were also evalu-
ated. No signiﬁcant increase was measured in either of the two
T-cell populations in the lungs of both MN  and IM young vaccinated
groups (supplementary Fig. 2A and B). Similarly, characterization of
CD4+ and CD8+ T-cells in the spleens of young mice did not reveal
signiﬁcant cellular immune responses (supplementary Fig. 2C and
D). Both MN and IM young mice vaccinated with inﬂuenza sub-
unit vaccine demonstrated reduced numbers of CD4+ and CD8+
T-cells when compared to the levels measured in adult MN  vacci-
nated mice (data not shown). These results indicate that in young
mice, delivery of subunit inﬂuenza vaccine induces a limited activa-
tion of the cellular response and that the protection observed after
challenge is mediated by humoral responses.
3.5. Evaluation of activated follicular B helper T (Tfh) cells and
germinal center formation
Several studies have demonstrated the fundamental role of
TFH cells for the generation of adaptive immunity, immunolog-
ical memory and the formation of germinal centers (GCs). We
measured a two-fold increase in the numbers of double-positive
CD4+ and CD44high T cells in the inguinal lymph nodes of young
mice immunized via the MN route when compared to the numbers
observed in the IM immunized group (Fig. 4B). GCs are formations
within secondary lymphoid organs in which the B cell response
against an antigen occurs. We  detected elevated numbers of dou-
ble positive FAS and PNA CD19 positive lymphocytes (activated
GCs) in regional lymph nodes of young mice immunized via MN
patches and a 3-fold increase when compared to the numbers
measured in young mice immunized via the IM route (Fig. 4A).
These results indicate that delivery of inﬂuenza subunit vaccine via
the skin with MN patches enhances TFH cell levels and increases
formation of GCs, leading to an improved antigen-speciﬁc B cell
response.
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Fig. 4. Analysis of activated follicular B helper T cells and germinal center formation. The numbers of GCs (A) and Tfh cells (B) from the inguinal lymph nodes were
determined by FACS analysis 7 days post immunization in 2-week-old mice vaccinated with microneedles or intramuscularly. Data represent the mean ± SD, *p < 0.05,
**p  < 0.005, ***p < 0.0001.
4. Discussion
Skin is the largest immunological organ of the human body [37].
It is composed of two primary layers, the epidermis and dermis [38].
In both layers, populations of specialized APCs with unique pheno-
typic and functional roles are present: Langerhans cells (LCs) are
abundant in the epidermis and dermal dendritic cells (dDCs) are
enriched in the dermis [39–42]. These two populations can be dis-
tinguished based on their surface markers: LCs express CD207 and
CD205 and differential levels of CD11b, while dDCs express CD11b
and CD205, but not CD207 [43,44]. Additionally, these two cell
populations are characterized by differences in chemokine receptor
expression and cytokine release [45].
This is the ﬁrst study, to our knowledge, that demonstrates
improved immune responses and improved protection in young
mice after delivery of an inﬂuenza vaccine through the skin using
MN patches. It has been estimated that each year, inﬂuenza infec-
tion in the U.S. is responsible for more than 20,000 childhood
hospitalizations and more than 100 pediatric deaths. Despite the
increased risk from infection, vaccination rates remain low with an
average rate of 40% annually. These data strongly support the need
for new, more effective inﬂuenza vaccines or vaccination routes
that can induce improved immune responses and protection, and
increased vaccine compliance and vaccination coverage in this high
risk group. Multiple factors could be responsible for reduced T cell
activation, reduced activation of GCs and an overall reduction in
adaptive immune responses [29]. The skin represents an ideal tar-
get organ for vaccine delivery because it contains a large network of
professional APCs that will take up antigen and migrate to the prox-
imal lymph nodes to activate T and B cells, initiating the adaptive
immune responses. Previous studies from our group and other have
demonstrated the immunological advantages after skin delivery of
inﬂuenza vaccine in adults [29,30]. In the present study, we demon-
strate improved humoral immune responses after skin delivery of a
single dose of inﬂuenza subunit vaccine using microneedle patches
in young mice, when compared to intramuscular immunization.
These improved humoral responses observed in young mice cor-
related with higher numbers of antibody-secreting cells in their
bone marrow. Germinal centers are formations within secondary
lymphoid organs where the process of B cell differentiation, pro-
liferation, maturation, clone selection and class switch is occurring
[46]. The processes taking place inside germinal centers will deﬁne
the quality of the B cell response to a speciﬁc antigen [47]. In this
process, B cells constantly migrate between the light and dark zones
within germinal centers during which the selection of long-lived B
cells with high afﬁnity for the antigen will occur [48]. The higher
number of activated GCs measured in the inguinal lymph nodes of
young mice 7 days post skin vaccination with inﬂuenza subunit vac-
cine correlates with the increased numbers of ASCs and improved
humoral immune responses observed in this group, when com-
pared to the intramuscularly immunized young mice, and may
be responsible for the more rapid virus clearance and complete
survival seen after lethal challenge. TFH cells are essential for the
regulation of B cell differentiation into plasma cells and memory B
cells thus playing a fundamental role in the generation of immuno-
logical memory [49,50]. TFH cells play a critical role in mediating
the selection of B cells and regulating their survival. These selected
B cells will further differentiate into high afﬁnity antibody secret-
ing cells (ASCs) or memory B cells that will be rapidly re-activated
upon encounter with a similar antigen [51]. We  observed increased
numbers of TFH cells in the proximal lymph nodes of young mice
immunized via microneedles, which are probably the result of
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better antigen processing and presentation by antigen-presenting
cells residing in the dermis and epidermis.
The signiﬁcant differences observed in responses to the two
routes of immunization used in young mice validate the use of
this model, and support previous results showing the beneﬁts
of skin delivery of inﬂuenza vaccine using microneedle patches
[29,31]. In addition to immunological advantages, microneedle skin
vaccination offers logistical advantages, such as ease of administra-
tion, rapid transport and delivery, lack of a requirement for highly
trained personnel to administer the vaccine as needed for intra-
muscular injection, and little or no bio-hazardous waste [30]. In
contrast, the currently used intramuscular vaccination approach
delivers the vaccine to the muscle, an area with reduced num-
bers of APCs to take up and process the antigen, leading to reduced
immune responses [29,52]. Furthermore, recent studies among vol-
unteers have demonstrated a preference for this route of vaccine
delivery over the conventional IM route [53]. Several factors might
contribute to this preference, such as needle phobia, lack of pain,
and the potential for self-administration. These factors could also
play a crucial role in improving inﬂuenza vaccine compliance and
coverage among the population [53]. Although in our study the
MN  patches only contained one inﬂuenza strain, it is highly likely
that MN delivery of the trivalent or quadrivalent vaccine will have
also enhance the immune response. Previous studies that com-
pared the magnitude of the immune response when delivering a
single inﬂuenza strain, or multiple inﬂuenza strains, failed to show
any signs of antigenic competition [54]. In addition, the large num-
ber of skin APCs and the fast rate of repopulation within 24 h [45]
minimize the possibility of differences in the immune response
to inﬂuenza antigens when delivering either trivalent or quadri-
valent inﬂuenza vaccine. Taking under consideration the logistical
advantages which this technology offers as well as the possibility of
administering other pediatric vaccines, we consider this approach
to skin immunization to be a very promising vaccination strategy
that will improve inﬂuenza-related outcomes in all age groups of
the population.
Authors contribution
DGK conceived, designed, and executed the study, collected and
analyzed data, and prepared the article. ESE, SM,  PK, JWL, IS, TLD,
and JK contributed to and assisted in experiments related to this
study. MRP  and RWC  revised and approved the ﬁnal version of this
manuscript.
Acknowledgements
We thank Ms.  Erin-Joi Collins for her valuable assistance in the
preparation and submission of this manuscript. This study was sup-
ported by the National Institutes of Health: HHSN266200700006,
U01EB012495, and AI110680. The funders had no role in the prepa-
ration and submission of the manuscript.
Conﬂict of interest: MRP  is an inventor of patents that have
been licensed to companies developing microneedle-based prod-
ucts, is a paid advisor to companies developing microneedle-based
products and is a founder/shareholder of companies developing
microneedle-based products. This potential conﬂict of interest has
been disclosed and is managed by Georgia Tech and Emory Uni-
versity. The other authors have no known conﬂicts of interest to
declare.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2015.01.086.
References
[1] Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM,  Mootrey G, et al. Preven-
tion and control of inﬂuenza: recommendations of the Advisory Committee on
Immunization Practices (ACIP), 2008. MMWR  Recomm Rep 2008;57:1–60.
[2] Monto AS. Seasonal inﬂuenza and vaccination coverage. Vaccine
2010;28(Suppl. 4):D33–44.
[3] Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NH,
et  al. Inﬂuenza vaccine effectiveness in preventing hospitalization for pneumo-
nia  in the elderly. Am J Epidemiol 1992;136:296–307.
[4] Baldo V, Baldovin T, Pellegrini M,  Angiolelli G, Majori S, Floreani A, et al.
Immunogenicity of three different inﬂuenza vaccines against homologous and
heterologous strains in nursing home elderly residents. Clin Dev Immunol
2010;2010:517198.
[5] Glathe H, Bigl S, Grosche A. Comparison of humoral immune responses to triva-
lent inﬂuenza split vaccine in young, middle-aged and elderly people. Vaccine
1993;11:702–5.
[6] Anar C, Bicmen C, Yapicioglu S, Unsal I, Halilcolar H, Yilmaz U.  Evaluation of
clinical data and antibody response following inﬂuenza vaccination in patients
with chronic obstructive pulmonary disease. New Microbiol 2010;33:117–27.
[7] Bickel M,  Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, et al. Low rate
of  seroconversion after vaccination with a split virion, adjuvanted pandemic
H1N1 inﬂuenza vaccine in HIV-1-infected patients. AIDS 2010;24:F31–5.
[8] Nolan T, McVernon J, Skeljo M,  Richmond P, Wadia U, Lambert S, et al. Immuno-
genicity of a monovalent 2009 inﬂuenza A(H1N1) vaccine in infants and
children: a randomized trial. JAMA 2010;303:37–46.
[9] Schmidt-Ott R, Schwarz T, Haase R, Sander H, Walther U, Fourneau M,
et al. Immunogenicity and reactogenicity of a trivalent inﬂuenza split vac-
cine in previously unvaccinated children aged 6–9 and 10–13 years. Vaccine
2007;26:32–40.
[10] Ding H, Santibanez TA, Jamieson DJ, Weinbaum CM,  Euler GL,  Grohskopf LA,
et  al. Inﬂuenza vaccination coverage among pregnant women – National 2009
H1N1 Flu Survey (NHFS). Am J Obstet Gynecol 2011;204:S96–106.
[11] Omer SB, Goodman D, Steinhoff MC,  Rochat R, Klugman KP, Stoll BJ, et al.
Maternal inﬂuenza immunization and reduced likelihood of prematurity and
small for gestational age births: a retrospective cohort study. PLoS Med
2011;8:e1000441.
[12] Rothberg MB,  Haessler SD, Brown RB. Complications of viral inﬂuenza. Am J
Med  2008;121:258–64.
[13] Brydak LB, Roszkowska-Blaim M,  Machala M, Leszczynska B, Sieniawska M.
Immunological response to inﬂuenza vaccination in children with renal failure.
Nephrol Dial Transplant 2001;16:643–4.
[14] Andreeva NP, Petrova TI, Golubtsova OI, Kozhevnikova SL, Kostinov MP,
Karpocheva SV, et al. Effect of vaccination against pneumococcal infection
and  inﬂuenza in children with asthma. Zh Mikrobiol Epidemiol Immunobiol
2007;7:4–7.
[15] Centers for Disease Control and Prevention. Prevention and control of inﬂuenza
with vaccines: interim recommendations of the Advisory Committee on Immu-
nization Practices (ACIP), 2013. MMWR  Morbidity and mortality weekly report,
vol. 62; 2013. p. 356.
[16] Thompson WW,  Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al.
Mortality associated with inﬂuenza and respiratory syncytial virus in the
United States. JAMA 2003;289:179–86.
[17] Thompson WW,  Shay DK, Weintraub E, Brammer L, Bridges CB, Cox
NJ, et al. Inﬂuenza-associated hospitalizations in the United States. JAMA
2004;292:1333–40.
[18] Longini Jr IM,  Halloran ME.  Strategy for distribution of inﬂuenza vaccine to
high-risk groups and children. Am J Epidemiol 2005;161:303–6.
[19] Whitley RJ, Monto AS. Prevention and treatment of inﬂuenza in high-risk
groups: children, pregnant women, immunocompromised hosts, and nursing
home residents. J Infect Dis 2006;194(Suppl. 2):S133–8.
[20] Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME,  Glover MJ,  et al.
Inﬂuenza-associated deaths among children in the United States, 2003–2004.
N Engl J Med  2005;353:2559–67.
[21] Heikkinen T, Peltola V. Inﬂuenza vaccination of children. Lancet Infect Dis
2009;9:720–1.
[22] Belshe RB, Edwards KM,  Vesikari T, Black SV, Walker RE, Hultquist M,  et al. Live
attenuated versus inactivated inﬂuenza vaccine in infants and young children.
N  Engl J Med  2007;356:685–96.
[23] Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of inﬂuenza vac-
cination in speciﬁc populations: children and the elderly. Expert Rev Vaccines
2012;11:973–84.
[24] Kang EK, Lim JS, Lee JA, Kim DH. Comparison of immune response by virus
infection and vaccination to 2009 pandemic inﬂuenza A/H1N1 in children. J
Korean Med  Sci 2013;28:274–9.
[25] Pabst LJ, Chaves SS, Weinbaum C. Trends in compliance with two-dose
inﬂuenza vaccine recommendations among children aged 6 months through 8
years. Vaccine 2013.
[26] He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW,  Lewis DB, et al. Cel-
lular immune responses in children and adults receiving inactivated or live
attenuated inﬂuenza vaccines. J Virol 2006;80:11756–66.
[27] Lambert LC, Fauci AS. Inﬂuenza vaccines for the future. N Engl J Med
2010;363:2036–44.
[28] Monto AS, Ohmit SE. Seasonal inﬂuenza vaccines: evolutions and future trends.
Expert Rev Vaccines 2009;8:383–9.
4682 D.G. Koutsonanos et al. / Vaccine 33 (2015) 4675–4682
[29] Koutsonanos DG, del Pilar Martin M,  Zarnitsyn VG, Jacob J, Prausnitz MR,  Com-
pans RW,  et al. Serological memory and long-term protection to novel H1N1
inﬂuenza virus after skin vaccination. J Infect Dis 2011;204:582–91.
[30] Sullivan SP, Koutsonanos DG, Del Pilar Martin M,  Lee JW,  Zarnitsyn V, Choi SO,
et  al. Dissolving polymer microneedle patches for inﬂuenza vaccination. Nat
Med  2010;16:915–20.
[31] Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherb-
hai MT,  et al. Delivery of subunit inﬂuenza vaccine to skin with microneedles
improves immunogenicity and long-lived protection. Sci Rep 2012;2:357.
[32] Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal
inﬂuenza vaccines administered by Soluvia licensed micro injection system.
Hum Vaccines Immunother 2012;8:67–75.
[33] Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(®) Intradermal vaccine:
a  promising new chance to increase the acceptability of inﬂuenza vaccination
in  adults. Expert Rev Vaccines 2012;11:17–25.
[34] Koutsonanos DG, Compans RW,  Skountzou I. Targeting the skin for microneedle
delivery of inﬂuenza vaccine. Adv Exp Med  Biol 2013;785:121–32.
[35] Koutsonanos DG, del Pilar Martin M,  Zarnitsyn VG, Sullivan SP, Compans RW,
Prausnitz MR,  et al. Transdermal inﬂuenza immunization with vaccine-coated
microneedle arrays. PloS ONE 2009;4:e4773.
[36] McElhaney JE. Inﬂuenza vaccine responses in older adults. Ageing Res Rev
2011;10:379–88.
[37] Jepps OG, Dancik Y, Anissimov YG, Roberts MS.  Modeling the human skin barrier
–  towards a better understanding of dermal absorption. Adv Drug Deliv Rev
2013;65:152–68.
[38] Skountzou I, Quan FS, Jacob J, Compans RW,  Kang SM.  Transcutaneous
immunization with inactivated inﬂuenza virus induces protective immune
responses. Vaccine 2006;24:6110–9.
[39] Banchereau J, Steinman RM.  Dendritic cells and the control of immunity. Nature
1998;392:245–52.
[40] Steinman RM.  Dendritic cells and the control of immunity: enhancing the efﬁ-
ciency of antigen presentation. Mt  Sinai J Med  2001;68:160–6.
[41] Schroder JM,  Reich K, Kabashima K, Liu FT, Romani N, Metz M,  et al. Who  is really
in  control of skin immunity under physiological circumstances – lymphocytes,
dendritic cells or keratinocytes. Exp Dermatol 2006;15:913–29.
[42] Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and
beyond. Semin Immunol 2007;19:48–55.
[43] Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY, et al.
Distinct dendritic cell populations sequentially present antigen to CD4T
cells and stimulate different aspects of cell-mediated immunity. Immunity
2003;19:47–57.
[44] Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y,
et  al. Langerin, a novel C-type lectin speciﬁc to Langerhans cells, is an endo-
cytic receptor that induces the formation of Birbeck granules. Immunity
2000;12:71–81.
[45] del Pilar Martin M,  Weldon WC,  Zarnitsyn VG, Koutsonanos DG, Akbari H,
Skountzou I, et al. Local response to microneedle-based inﬂuenza immuniza-
tion in the skin. MBio 2012;3, e00012-12.
[46] Boyden AW,  Frickman AM,  Legge KL, Waldschmidt TJ. Primary and long-term
B-cell responses in the upper airway and lung after inﬂuenza A virus infection.
Immunol Res 2014.
[47] O E, Ko EJ, Kim MC,  Lee YT, Song JM,  Kwon YM, et al. Distinct B-cell popula-
tions contribute to vaccine antigen speciﬁc-antibody production in a transgenic
mouse model. Immunology 2014.
[48] Rothaeusler K, Baumgarth N. B-cell fate decisions following inﬂuenza virus
infection. Eur J Immunol 2010;40:366–77.
[49] Crotty S. Follicular helper CD4T cells (TFH). Annu Rev Immunol 2011;29:
621–63.
[50] Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG.  Follicular
helper T cells: lineage and location. Immunity 2009;30:324–35.
[51] Takemori T, Kaji T, Takahashi Y, Shimoda M,  Rajewsky K. Generation of memory
B  cells inside and outside germinal centers. Eur J Immunol 2014;44:1258–64.
[52] Berzofsky JA, Ahlers JD, Belyakov IM.  Strategies for designing and optimizing
new generation vaccines. Nat Rev 2001;1:209–19.
[53] Norman JJ, Arya JM,  McClain MA,  Frew PM,  Meltzer MI, Prausnitz MR.  Micronee-
dle  patches: usability and acceptability for self-vaccination against inﬂuenza.
Vaccine 2014;32:1856–62.
[54] Van der Vliet D, Pepin S, Lambert M,  Fauchoux N, Donazzolo Y, Dupuy M,  et al.
Similar immunogenicity of the A/H1N1 2009 pandemic inﬂuenza strain when
used as a monovalent or a trivalent vaccine. Hum Vaccin 2010;6:823–8.
